An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
Authors
Keywords
-
Journal
CNS DRUGS
Volume 33, Issue 9, Pages 919-932
Publisher
Springer Science and Business Media LLC
Online
2019-08-17
DOI
10.1007/s40263-019-00656-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nusinersen in later-onset spinal muscular atrophy
- (2019) Basil T. Darras et al. NEUROLOGY
- RNA-Targeted Therapeutics
- (2018) Stanley T. Crooke et al. Cell Metabolism
- Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
- (2018) Eugenio Mercuri et al. NEUROMUSCULAR DISORDERS
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
- (2018) Yuko Shimizu-Motohashi et al. Orphanet Journal of Rare Diseases
- Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2ʹ-MOE-Modified Antisense Oligonucleotide
- (2018) Padmakumar Narayanan et al. TOXICOLOGICAL SCIENCES
- The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
- (2018) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Nusinersen in spinal muscular atrophy type 1 patients older than 7 months
- (2018) Karolina Aragon-Gawinska et al. NEUROLOGY
- Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care
- (2018) Valeria A Sansone et al. NEUROLOGICAL SCIENCES
- 218th ENMC International Workshop:
- (2017) Richard S. Finkel et al. NEUROMUSCULAR DISORDERS
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
- (2017) Xiulong Shen et al. NUCLEIC ACIDS RESEARCH
- Assessment of the Effects of 2′-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates
- (2017) Scott P. Henry et al. Nucleic Acid Therapeutics
- The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
- (2017) Stanley T. Crooke et al. Nucleic Acid Therapeutics
- Intrathecal Injections in Children With Spinal Muscular Atrophy
- (2016) Manon Haché et al. JOURNAL OF CHILD NEUROLOGY
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
- (2016) Stanley T Crooke et al. MOLECULAR THERAPY
- Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
- (2016) Claudia A. Chiriboga et al. NEUROLOGY
- Physician driven variation in the care of children with spinal muscular atrophy type 1
- (2016) Maryam Oskoui et al. PEDIATRIC PULMONOLOGY
- Should children with overweight or obesity be excluded from height references?
- (2015) Pétur B Júlíusson et al. ARCHIVES OF DISEASE IN CHILDHOOD
- Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials
- (2015) Raju Panta et al. Journal of Clinical Lipidology
- 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7–9 November 2014, Heemskerk, The Netherlands
- (2015) Richard Finkel et al. NEUROMUSCULAR DISORDERS
- Liver histology during Mipomersen therapy for severe hypercholesterolemia
- (2014) Nikroo Hashemi et al. Journal of Clinical Lipidology
- Antisense Oligonucleotide Therapies
- (2014) Kendall S. Frazier TOXICOLOGIC PATHOLOGY
- Headache after lumbar puncture: randomised crossover trial of 22-gauge versus 25-gauge needles
- (2013) Catherine Crock et al. ARCHIVES OF DISEASE IN CHILDHOOD
- Spinal muscular atrophy: going beyond the motor neuron
- (2012) Gillian Hamilton et al. TRENDS IN MOLECULAR MEDICINE
- International survey of physician recommendation for tracheostomy for spinal muscular atrophy Type I
- (2011) Renée C. Benson et al. PEDIATRIC PULMONOLOGY
- Newborn and carrier screening for spinal muscular atrophy
- (2010) Thomas W. Prior et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
- (2010) C. Frank Bennett et al. Annual Review of Pharmacology and Toxicology
- Spinal muscular atrophy: a time for screening
- (2010) Thomas W Prior CURRENT OPINION IN PEDIATRICS
- Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
- (2010) Y. Hua et al. GENES & DEVELOPMENT
- Incidence of Spinal Muscular Atrophy in Poland – More Frequent than Predicted?
- (2010) Maria Jedrzejowska et al. NEUROEPIDEMIOLOGY
- A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy
- (2009) Eva Arkblad et al. ACTA PAEDIATRICA
- Spinal muscular atrophy
- (2008) Mitchell R Lunn et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started